DENVER, June 4 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, is exhibiting its AspirinWorks(R) Test at the American Diabetes Association's 68th Scientific Sessions. The exhibits are open Saturday through Monday, June 7 - 9, 2008, at the Moscone Convention Center in San Francisco, Calif.
This marks the first time the AspirinWorks test will be exhibited at the American Diabetes Association (ADA) Scientific Sessions. Corgenix representatives will be on-hand during the conference at booth 738 to answer questions about the AspirinWorks Test, including ongoing clinical research and the relationship among diabetes, aspirin effect and cardiovascular disease.
Corgenix is presenting an abstract on aspirin effect and diabetes during the general poster session on Saturday, June 7 in Hall D from 11:30 a.m. until 1:30 p.m. The abstract examines possible differences between healthy and diabetic men and women in heart attack and stroke risk reduction based on their response to the anti-clotting effects of aspirin.
AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.
Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.
The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to
determine levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine,
which aids in the qualitative detection of aspirin effect in apparently
|SOURCE Corgenix Medical Corporation|
Copyright©2008 PR Newswire.
All rights reserved